Newsroom

May 2019

• 
  Story May 17, 2019 Discovery

  Respiratory clinical trials: Putting patients at the heart of research

  All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

• Press release May 16, 2019

  Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

  Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO   Primary…
• Featured News May 15, 2019

  SOLAR-1 NEJM Publication

• Press release May 10, 2019

  Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

  Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya® (fingolimod) 0.5mg had significantly fewer relapses than patients…
• 
  Story May 09, 2019 Discovery

  Women in Science: Sandrine Piret-Gérard

  Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.

• Press release May 09, 2019

  Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's…
• Ad hoc release May 09, 2019

  Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

  Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline…
• Press release May 08, 2019

  Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

  Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…
• Press release May 07, 2019

  New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

  Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial  Mean age of follow-up since dosing…
• Press release May 07, 2019

  Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS

  Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or…
• Press release May 05, 2019

  AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

  Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101…
• Press release May 02, 2019

  Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN

  After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average  Separate study…